TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05655728
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The participants will receive treatment of metformin (initial dose of 500 mg/day, within 2 weeks reaching the maximum tolerated dose \[maximum: 1500 mg/day\]).
Study: NCT05676294
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg of oral olanzapine one hour prior to ambulatory surgery
Study: NCT06555471
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab: 200mg iv q3w d1
Study: NCT06555471
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: po d1-d14，q3w； according to body surface area ：\<1.5m\^2 40mg/time；1.5\~1.8m\^2 50mg/time；\>1.8m2 60mg/time)
Study: NCT06174116
Drug: Lumateperone
Normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
Study: NCT05453955
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia induction and maintenance with propofol 60 minutes later, change the maintenance drug to remimazolam
Study: NCT05453955
Drug: Remimazolam Besylate
Normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anesthesia induction and maintenance with remimazolam 60 minutes later, change the maintenance drug to propofol
Study: NCT00004194
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04731922
Drug: TAK-510
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-510 solution.
Study: NCT04629976
Drug: NCO-48 Fumarate 4 mg
Normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 2mg NCO-48 Fumarate over 28 days of therapy
Study: NCT04629976
Drug: NCO-48 Fumarate 20 mg
Normalized name: Ad5-nCoV
DrugBank: Ad5-nCoV (DB15655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 10 mg NCO-48 Fumarate over 28 days of therapy
Study: NCT04629976
Drug: Tenofovir Alafenamide 25 mg
Normalized name: tenofovir alafenamide 25 MG
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg over 28 days of therapy
Study: NCT05867212
Drug: Cabotegravir Injection [Apretude]
Normalized name: cabotegravir Injection [Apretude]
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: People who want to get the long acting injectable will have the option in participating in surveys after their visit and have their electronic health records reviewed.
Study: NCT05606380
Drug: HLX60
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HLX60(anti-GARP Monoclonal Antibody）have 5 dose cohorts: 0.5, 2, 5, 15, 25mg/kg, intravenous infusion, every 3 weeks.
Study: NCT04804904
Drug: TQ-B3101
Normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ-B3101 oral capsule
Study: NCT06013319
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
Study: NCT05030597
Drug: 68Ga-DOTA-FAPI
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous access is pre-established. Quality control is carried out to confirm the radiochemical purity of 68Ga-DOTA-FAPI by HPLC. Intravenous administration of 68Ga-DOTA-FAPI according to 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
Study: NCT05810363
Drug: Etomidate - propofol mixture
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive etomidate - propofol mixture during induction and maintenance. Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，EP mixture（E：P=1:2） 0.1-0.25 ml/kg for induction, EP mixture 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
Study: NCT05810363
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive propofol during induction and maintenance.Sufentanil 0.2-0.7 μg/kg，Cisatracurium 0.15 mg/kg，propofol 0.1-0.25 ml/kg for induction, propofol 0.4\~ 1.2 ml/kg/h and remifentanil 0.05μg/kg/min \~0.3 μg/kg/min for maintenance.
Study: NCT05156788
Drug: PD-1+Lenvatinib+GEMOX
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tilelizumab 200mg, add 0.9% NS 100mL, d1 Q3W, Lenvatinib 8mg, po, qd Gemox chemotherapy: Gemcitabine 1000mg/m2 with 0.9% NS 100mL, 30 minutes, d1, 8, Q3W, + oxaliplatin 85mg/m2 with 5%GS 500mL, 2 hours, d1, Q3W
Study: NCT04705350
Drug: Zampilimab
Normalized name: Zampilimab
DrugBank: Zampilimab (DB16381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.
Study: NCT04173390
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
Study: NCT05328076
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green is used to perform intraoperative angiography.
Study: NCT01108913
Drug: Bimosiamose
Normalized name: Bimosiamose
DrugBank: Bimosiamose (DB06197)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04472949
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab: 1500 mg iv
Study: NCT04472949
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin: AUC 5 mg/mL/min iv
Study: NCT04472949
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide: 100 mg/m2 iv
Study: NCT00002306
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05798819
Drug: GLS-010
Normalized name: Anti-pd-1 monoclonal antibody gls-010
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05798819
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT05798819
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05798819
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT05798819
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT03570814
Drug: Administration of Albendazole on Day 1
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Albendazole 400mg on study day 1.
Study: NCT03570814
Drug: Administration of Ivermectin on Day 1
Normalized name: ivermectin Topical Solution [Iver-On]
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
Study: NCT05069935
Drug: FT538
Normalized name: Fidanacogene elaparvovec
DrugBank: Fidanacogene elaparvovec (DB16783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT538 is an allogeneic natural killer (NK)-cell immunotherapy
Study: NCT05069935
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lympho-conditioning agent
Study: NCT05330208
Drug: SHR-1816
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1816
Study: NCT05944445
Drug: Linezolid 600 mg
Normalized name: linezolid 600 MG
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 600mg injection
Study: NCT00002097
Drug: Nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04586712
Drug: Active CBD
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be provided a viscous liquid in a bottle with a syringe dropper containing CBD-extract oil at concentrations of 2000mg/30mL (high).
Study: NCT04586712
Drug: Vehicle Control (Placebo)
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be provided a viscous liquid in a bottle with a syringe dropper containing placebo containing no CBD oil (0mg/30 mL).
Study: NCT06106802
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib 240mg/day
Study: NCT06106802
Drug: Tepotinib
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tepotinib 500mg/day
Study: NCT06204796
Drug: vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
Study: NCT06204796
Drug: Systemic prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
Study: NCT04625088
Drug: Atropine + Standardized liquid test meal
Normalized name: bone meal
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.
Study: NCT06356415
Drug: Bupivacaine injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group one will receive infraclavicular block using bupivacaine
Study: NCT06356415
Drug: Bupivacaine+ Dexamethasone+ Dexmedetomidine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group two will receive infraclavicular block using dexamethasone and dexmedetomidine added to the bupivacaine
Study: NCT04942522
Drug: placebo (Microcrystalline cellulose )
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/capsule
Study: NCT06029049
Drug: Modified Time Principle Induction (MTPI) with rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be induced using lidocaine 1 mg/kg IV, an opioid such a fentanyl (1-2 mcg/kg) IV, followed by 0.6 mg/kg IV rocuronium, and IV propofol with dosage at the discretion of the care team, administered within 10 seconds of rocuronium and the intubation will be performed with a C-MAC
Study: NCT03743298
Drug: AV-MEL-1
Normalized name: Mel
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
Study: NCT06177015
Drug: Darolutamide continuous
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: standard of care
Study: NCT06177015
Drug: Darolutamide intermittent
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: experimental group
Study: NCT05081089
Drug: Primaquine Phosphate
Normalized name: Primaquine Phosphate
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.
Study: NCT05081089
Drug: Sulphadoxine-pyrimethamine with amodiaquine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfadoxine/pyrimethamine tablets contain 500mg sulfadoxine and 25mg pyrimethamine. Amodiaquine tablets contain 150mg amodiaquine (as hydrochloride). Tablets will be administered according to weight as per manufacturer guidelines.
Study: NCT05081089
Drug: Tafenoquine
Normalized name: tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg tafenoquine tablets are prepared into a 1mg/mL solution in water. Solution will be given according to weight as indicated per treatment arm in 5kg bands.
Study: NCT06363734
Drug: Osimertinib plus Dalpiciclib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle
Study: NCT02432417
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
Study: NCT04729244
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hemp Oil
Study: NCT05179057
Drug: Posoleucel
Normalized name: Posoleucel
DrugBank: Posoleucel (DB17974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as 2-4 milliliter infusion, visually identical to placebo
Study: NCT05851768
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.25%
Study: NCT05851768
Drug: Bupivacaine + Magnesium
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.25% + Magnesium
Study: NCT05851768
Drug: Bupivacaine + Dexmedetomidine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.25% + Dexmedetomidine
Study: NCT04419181
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose: 75 mg/m2 q3w
Study: NCT04419181
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: area under the concentration-time curve \[AUC\] 6 q3w
Study: NCT04419181
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 8-mg/kg loading dose, 6-mg/kg maintenance dose q3w
Study: NCT04419181
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 840-mg loading dose, 420-mg maintenance dose q3w
Study: NCT04419181
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose: 3.6mg/kg q3w
Study: NCT00085345
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00085345
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05206890
Drug: fluzoparib monotherapy or combination therapy
Normalized name: Medicated Pad or Tape
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer who underwent fluzoparib monotherapy or combination therapy
Study: NCT05282771
Drug: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study drug is to be self-administered by applying as a thin layer once daily to cover only affected areas and rubbed in gently for approximately 8 weeks.
Study: NCT05553613
Drug: Ticagrelor 90 MG Oral Tablet
Normalized name: TICAGRELOR 90 mg ORAL TABLET
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT05553613
Drug: Clopidogrel tablet
Normalized name: Clopidogrel Tablets
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke and possible adverse effects.
Study: NCT04542148
Drug: Sliding Scale Insulin
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
Study: NCT05551910
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients in the test group were given esmketamine (50mg / 2ml \* branch, Jiangsu Hengrui Pharmaceutical Co., Ltd.) 0.15-0.5mg/kg H was pumped intravenously. Two minutes after the administration, the pain was scored with the cpot pain observation scale. The target cpot was \< 3 points. The dose of esketamine was adjusted according to the cpot score.
Study: NCT05551910
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol
Study: NCT04741087
Drug: AMT-101 (oral)-Dose A
Normalized name: OXT-101
DrugBank: AMT-101 (DB18555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMT-101 is an orally administered biologic therapeutic, taken once daily.
Study: NCT04741087
Drug: AMT-101 (oral)-Dose B
DrugBank: AMT-101 (DB18555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMT-101 is an orally administered biologic therapeutic, taken once daily.
Study: NCT04542148
Drug: Continuous Insulin Infusion
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
Study: NCT04710017
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will be given Tranexamic acid at 500 mg four times daily (2 g/day) during the bleeding episodes for 5 days. The dose is 250 mg.
Study: NCT04710017
Drug: Medroxyprogesterone Acetate 150 MG/ML
Normalized name: medroxyprogesterone acetate 150 MG/ML
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will be given MPA at 150 mg once intramuscular injection
Study: NCT05357027
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.
Study: NCT05357027
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT05747313
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal.
Study: NCT05821192
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375mg/m2 by IV infusion once every 3 weeks
Study: NCT05821192
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 g/m2 on Days 1 by IV infusion once every 3 weeks
Study: NCT05821192
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg on Days 1 to 4 of each 3-week cycle by IV infusion
Study: NCT05821192
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 on Days 1 by IV infusion once every 3 weeks